SEGMENT AND SUBSIDIARY INFORMATION (Tables)

6 Months Ended

Jun. 30, 2011

SEGMENT AND SUBSIDIARY INFORMATION

Schedule of revenues

	Three Months Ended
	June 30,
	2011									2010^
	United States			Europe			Total			United States			Europe			Total
Sales:
CNS
Proprietary CNS
PROVIGIL*	$	237,684		$	13,462		$	251,146		$	268,550		$	16,280		$	284,830
NUVIGIL	58,576			—			58,576			40,968			—			40,968
GABITRIL	8,765			1,165			9,930			11,118			1,024			12,142
Other Proprietary CNS	—			2,608			2,608			—			2,652			2,652
Generic CNS	—			9,990			9,990			—			8,574			8,574
CNS	305,025			27,225			332,250			320,636			28,530			349,166
Pain
Proprietary Pain
FENTORA**	41,910			9,516			51,426			38,861			5,661			44,522
Other Proprietary Pain	—			—			—			—			49			49
Generic Pain
ACTIQ	14,607			15,387			29,994			14,471			14,067			28,538
Generic OTFC	6,015			—			6,015			11,535			—			11,535
AMRIX	13,554			—			13,554			28,548			—			28,548
Generic AMRIX	11,420			—			11,420			—			—			—
Other Generic Pain	—			28,224			28,224			—			21,556			21,556
Pain	87,506			53,127			140,633			93,415			41,333			134,748
Oncology
Proprietary Oncology
TREANDA	125,847			—			125,847			99,732			—			99,732
Other Proprietary Oncology	5,017			21,699			26,716			6,253			18,769			25,022
Generic Oncology	—			6,188			6,188			—			5,704			5,704
Oncology	130,864			27,887			158,751			105,985			24,473			130,458
Other
Other Proprietary	4,726			1,804			6,530			2,883			1,754			4,637
Other Generic	4,536			87,400			91,936			3,058			90,368			93,426
Other	9,262			89,204			98,466			5,941			92,122			98,063
Total Net Sales	532,657			197,443			730,100			525,977			186,458			712,435
Other Revenue	7,170			993			8,163			12,345			2,130			14,475
Total External Revenues	539,827			198,436			738,263			538,322			188,588			726,910
Inter-Segment Revenues	7,028			2,341			9,369			6,417			6			6,423
Elimination of Inter-Segment Revenues	(7,028		)	(2,341		)	(9,369		)	(6,417		)	(6		)	(6,423		)
Total Revenues	$	539,827		$	198,436		$	738,263		$	538,322		$	188,588		$	726,910

	Six Months Ended
	June 30,
	2011									2010^
	United States			Europe			Total			United States			Europe			Total
Sales:
CNS
Proprietary CNS
PROVIGIL*	$	481,027		$	28,515		$	509,542		$	513,151		$	34,130		$	547,281
NUVIGIL	110,608			—			110,608			75,890			—			75,890
GABITRIL	19,803			2,254			22,057			19,417			2,486			21,903
Other Proprietary CNS	—			4,961			4,961			—			5,658			5,658
Generic CNS	—			19,765			19,765			—			10,885			10,885
CNS	611,438			55,495			666,933			608,458			53,159			661,617
Pain
Proprietary Pain
FENTORA**	80,953			16,874			97,827			77,341			9,390			86,731
Other Proprietary Pain	—			61			61			—			108			108
Generic Pain
ACTIQ	30,093			28,056			58,149			29,411			32,558			61,969
Generic OTFC	15,038			—			15,038			24,314			—			24,314
AMRIX	36,586			—			36,586			53,683			—			53,683
Generic Amrix	11,420			—			11,420			—			—			—
Other Generic Pain	—			52,090			52,090			—			23,698			23,698
Pain	174,090			97,081			271,171			184,749			65,754			250,503
Oncology
Proprietary Oncology
TREANDA	243,572			—			243,572			180,989			—			180,989
Other Proprietary Oncology	10,520			41,433			51,953			10,808			38,960			49,768
Generic Oncology	—			12,366			12,366			—			9,858			9,858
Oncology	254,092			53,799			307,891			191,797			48,818			240,615
Other
Other Proprietary	10,731			4,018			14,749			8,247			1,754			10,001
Other Generic	11,687			193,671			205,358			7,154			119,226			126,380
Other	22,418			197,689			220,107			15,401			120,980			136,381
Total Net Sales	1,062,038			404,064			1,466,102			1,000,405			288,711			1,289,116
Other Revenue	14,853			2,421			17,274			28,129			6,250			34,379
Total External Revenues	1,076,891			406,485			1,483,376			1,028,534			294,961			1,323,495
Inter-Segment Revenues	12,289			2,429			14,718			15,336			6			15,342
Elimination of Inter-Segment Revenues	(12,289		)	(2,429		)	(14,718		)	(15,336		)	(6		)	(15,342		)
Total Revenues	$	1,076,891		$	406,485		$	1,483,376		$	1,028,534		$	294,961		$	1,323,495

^ Certain reclassifications of prior year amounts have been made to conform to current year presentation.

Europe- Primarily Europe, Middle East and Africa.

Proprietary products are products which are sold under patent coverage.

Generic products are products sold without patent coverage in the primary sales territory.

Patent coverage may exist in other territories.

* Marketed under the name MODIODAL® (modafinil) in France and under the name VIGIL® (modafinil) in Germany.

** Marketed under the name EFFENTORA® (fentanyl buccal tablet) in Europe.

Schedule of income (loss) before income taxes

	Three months ended						Six months ended
	June 30,						June 30,
	2011			2010			2011			2010
United States	$	202,364		$	156,188		$	520,259		$	298,030
Europe	(4,083		)	(541		)	(7,637		)	6,265
Total	$	198,281		$	155,647		$	512,622		$	304,295

Schedule of total assets

	June 30,		December 31,
	2011		2010
United States	$	3,963,015	$	3,297,595
Europe	1,790,071		1,594,238
Total	$	5,753,086	$	4,891,833